Cetera Advisor Networks LLC Halozyme Therapeutics, Inc. Transaction History

Cetera Advisor Networks LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $38,967 - $48,536	1,157 Added 8.08%	15,475 $629,000
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $109,322 - $138,130	3,281 Added 29.73%	14,318 $529,000
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $402,409 - $485,959	11,037 New	11,037 $421,000
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $31,677 - $53,694	964 Added 13.27%	8,227 $314,000
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $66,179 - $98,194	1,652 Added 29.44%	7,263 $413,000
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $3,429 - $4,608	89 Added 1.61%	5,611 $222,000
Q2 2022 Aug 11, 2022	BUY	$37.35 - $48.3 $206,246 - $266,712	5,522 New	5,522 $243,000
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $643 - $740	-25 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $406 - $670	25 New	25 $1,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.